Performance and Safety of Lyoplant® in Guided Bone Regeneration (GBR) in Oral Surgery

Inclusion Criteria: * Patients who are willing to give a voluntary consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the Informed Consent Form (ICF). * Patients with the capacity to consent for themselves. * Patients in need of an implant with a simultaneous GBR procedure. * Presence of buccal bony dehiscence with a vertical defect height (VDH) ≥ 1 mm and ≤ 6 mm after implant placing. * The tooth at the implant site must have been extracted or lost at least 8 weeks before the date of bone augmentation (volumetrically healed site). Exclusion Criteria: * Patients \< 18 years. * Currently pregnant or breastfeeding women. * Major systemic diseases (e.g. recent myocardial infarction, cerebrovascular accident or valvular prosthesis surgery, a poorly stabilized diabetes mellitus, severe hypertension, severe peripheral artery occlusive disease, malignancies, autoimmune diseases, or kidney diseases, untreated or uncontrolled periodontal disease, uncontrolled drug or alcohol abuse, uncontrolled psychiatric disorders). * Acute infectious diseases. * Immunocompromised patients. * Serious disturbances of bone metabolism and/or serious bone diseases of endocrine etiology. * Medical conditions requiring prolonged use (\> 6 months) of steroids and/or ongoing treatment with gluco- and mineralocorticoids and with agents affecting calcium metabolism (e.g. calcitonin), and/or anticoagulative therapy. * Previous or current use of antiresorptive drugs (ARDs) (e.g. bisphosphonates, selective estrogen receptor modulators (SERMs), denosumab, hormone replacement therapy and calcitonin). * Previous oral / maxillofacial radiotherapy. * Heavy smoker (\>10 cigarettes/day). In the case of vapors with nicotine, the use of \>300 puff vapors (equivalent to 10 cigarettes/day) are not allowed. * Health conditions, which do not permit the surgical treatment. * Use of the Investigational Device / Comparator in infected areas. * Known foreign body sensitivity to implant materials. * Simultaneous participation in another interventional clinical trial (drugs or medical devices studies) if it could impact the result of the study.